Treatment of Persistent Moderate-to-Severe or Chronic Recurrent Dyshidrotic Eczema
Dyshidrotic eczema that follows a persistent, moderate-to-severe course, or that recurs chronically,
requires a structured escalation of care beyond initial topical and conservative measures. This protocol
addresses that specific scenario.
Clinical scenario
This protocol applies to patients with dyshidrotic eczema whose disease is persistent and graded as
moderate to severe, or whose condition is chronic or recurrent — and who have already received the
measures addressed in earlier treatment steps without achieving adequate disease control.
Treatment approach (partial summary)
At this stage, the protocol moves to systemic immunomodulatory therapy — a category
of agents that act beyond topical treatment. Several distinct options within this class are addressed,
along with the specific circumstances in which each is appropriate.
The complete regimen, agent selection criteria, and sequencing are in the full protocol.
References
DOI: 10.1111/ddg.15179
- In addition to measures of step 1 and step 2:
- Systemic immunomodulatory therapy, e.g.
- Alitretinoin
- Ciclosporin
- Anti-IL4/IL-13 antibodies
- JAK inhibitors
- Systemic glucocorticoids (only short-term in context of a treatment plan)
- Ciclosporin* should be used in patients with moderate to severe CHE refractory to first-line and second-line therapies or with contraindication for first-line and second-line therapies.
- Oral glucocorticoids may be used briefly for the treatment of acute, severe HE (in general, for a maximum of 3 weeks, starting with 0.5 mg/kg body weight (BW)/day dosage for prednisone, with instruction for rapid dose reduction in increments of 5–10 mg)) as part of a treatment plan, for example, at the beginning of other, slowly acting systemic therapies.
View source ↗